Miragen therapeutics, inc. (MGEN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net loss

-41,873

-32,703

-26,512

-17,274

-11,328

-7,890

-2,160

Issuance of common stock under subscription agreement

-

-

-

281

330

300

-

Share-based compensation expense

3,970

3,679

2,409

198

3,015

4,298

-

Non-cash interest expense

340

376

94

158

-

-

-

Depreciation and amortization

300

300

300

341

184

144

148

Amortization of premiums and discounts on available-for-sale securities

432

416

0

-

-

-

-

Change in fair value of preferred stock warrants

-

-

-

3

-

-

-

Loss on impairment of assets

-

-

-

-

0

-

-

Noncash interest on note payable  related party

-

-

-

-

132

1,007

1,937

Loss on extinguishment of debt

-

-

-

-

0

-

-

Lease termination

-

-

-

-

-

-46

-

Gain on legal settlement

-

-

-

-

-

100

250

Changes in operating assets and liabilities:
Accounts receivable

84

-1,432

1,436

20

-694

94

-202

Inventory

-

-

-

-

8

-178

187

Prepaid expenses and other assets

-126

-51

724

426

-28

-191

65

Deferred revenue

-

-

-

-519

-

-

-

Accounts payable

525

-335

-101

292

-

-

-

Accrued and other liabilities

1,084

791

-2,205

2,211

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

633

383

-280

Lease termination/abandonment payable

-

-

-

-

248

376

319

Net cash used in operating activities of discontinued operations

-

-

-

-

-

-

-194

Net cash used in operating activities

-36,056

-26,844

-28,167

-14,755

-6,898

-2,213

-1,168

Cash flows from investing activities:
Purchases of short-term investments

32,690

62,462

0

1,000

-

-

-

Maturities of short-term investments

61,000

33,000

0

1,000

-

-

-

Cash acquired in reverse merger

-

-

1,280

0

-

-

-

Proceeds from sale of property and equipment

-

-

0

-

-

-

-

Purchases of property and equipment

84

445

246

250

123

266

5

Decrease in security deposit on lease

-

-

-

-

28

-8

11

Net cash provided by (used in) investing activities

28,226

-29,907

1,034

-250

-95

-274

6

Cash flows from financing activities:
Proceeds from the sale of common stock and warrants

2,283

44,529

-

-

13,095

6,644

-500

Payment of issuance costs associated with the sale of common stock

77

3,037

-

-

-

-

-

Proceeds from issuance of notes payable

-

-

10,000

0

-

-

-

Proceeds from issuance of redeemable convertible preferred stock

-

-

-

16,091

-

-

-

Repayment of note payable  related party

-

-

-

-

-

-

10,461

Payments of principal on note payable

2,333

0

4,667

333

-

-

61

Proceeds from stock purchases under employee stock purchase plan

110

242

110

0

-

-

-

Proceeds from Stock Options Exercised

100

200

300

213

-

-

-

Payment of notes payable issuance costs

-

-

-

6

-

-

-

Proceeds from issuance of note payable/amounts due to related party

-

-

-

-

-

795

12,566

Proceeds from cash released from restricted cash account securing a letter of credit

-

-

-

-

50

-

-

Shares repurchased to satisfy tax withholding obligation for restricted stock awards

-

-

-

-

363

-

-

Repayment of capital lease obligation

-

-

-

-

76

42

-

Fractional shares repurchased upon reverse stock split

-

-

-

-

0

-

-

Distributions to member

-

-

-

-

-

-

285

Net cash provided by financing activities

70

41,916

52,470

15,874

12,706

7,397

1,259

Net increase (decrease) in cash and cash equivalents

-7,760

-14,835

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

869

5,713

4,910

97

Net decrease in cash and cash equivalents

-

-

25,337

-

-

-

-

Supplemental disclosure of cash flow information
Cash paid for interest

511

489

446

-

-

-

-

Cash paid for interest

-

-

-

164

6

1

1,209

Supplemental disclosure of non-cash investing and financing activities
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax

3

-3

0

-

-

-

-

Amortization of public offering costs

3

55

0

-

-

-

-

Unrealized Gain (Loss) on Investments

3

-3

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

76,981

0

-

-

-

Liabilities assumed, net of non-cash assets received in reverse merger

-

-

1,076

0

-

-

-

Issuance of warrant classified as equity

-

-

127

0

-

-

-

Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)

-

-

51

0

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

5

49

-

-

-

Asset acquired under capital lease

-

-

-

-

-

164

-

Private Financing
Proceeds from the sale of common stock

-

-

40,703

-

-

-

-

Payments of Stock Issuance Costs

-

-

1,216

-

-

-

-

Transfer of common stock issuance costs from prepaid expenses and other current assets to equity

-

-

331

-

-

-

-

At-the-market
Proceeds from the sale of common stock

-

-

7,862

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

330

-

-

-

-

Public offering
Proceeds from the sale of common stock

-

-

0

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

0

-

-

-

-

Shelf Registration
Payments of Stock Issuance Costs

-

-

299

-

-

-

-

At-the-market Offering [Member]
Transfer of common stock issuance costs from prepaid expenses and other current assets to equity

-

-

23

-

-

-

-